Tumor News and Research

RSS

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines. Clinical research will be conducted at NCRC. IRX Therapeutics will provide its proprietary IRX-2 immunomodulatory regimen, clinical trial design and technical support. This is the first collaboration of its kind between the NCRC and a U.S.-based biotechnology firm.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

A major research initiative to optimize quality of life for cancer survivors

At the age of 12, she was diagnosed with spinal cord cancer, with a nasty tumor sitting at the very base of her spinal cord and getting entangled with spinal nerves.

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

Caliper Life Sciences' first-quarter 2010 GAAP revenues increase 1% to $28.7M

Caliper Life Sciences, Inc., today reported its first quarter 2010 results.

29 Apr 2010

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it received approval for its AUTOMAGLIA 90 fully-automated ECLIA analyzer as well as Down Syndrome screening kit from the State Food and Drug Administration of China.

29 Apr 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Oncos Therapeutics completes $5.5M investment from HealthCap

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a - 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding - 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

29 Apr 2010

CINJ trial targets new combination therapy for advanced solid tumors

Building off recent laboratory discoveries relating to how cancer cells become resistant to therapies that attempt to starve cancer, scientists at The Cancer Institute of New Jersey (CINJ) are now applying that knowledge to a process in which cancer cells eat themselves to downsize and resist therapy. The ultimate goal of this effort is to improve upon current anticancer treatments.

29 Apr 2010

New report evaluating use of SBRT in lung cancer treatment released

The American Society for Radiation Oncology has released its Emerging Technology Committee's report evaluating the use of stereotactic body radiotherapy in lung cancer treatment.

29 Apr 2010

Geron reports net loss of $16.6M for first-quarter 2010

Geron Corporation today reported financial results for the three months ended March 31, 2010.

29 Apr 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Tumor cell factories may be difficult to defeat: Researchers

Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells.

29 Apr 2010

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month.

28 Apr 2010

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Cell Therapeutics, Inc. today announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. Additionally, the majority of breast cancers that are associated with the susceptibility mutation (BRCA1) are of the triple-negative type.

28 Apr 2010

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Usually when all else fails with a technical device, a "reset" button can be pressed, preventing a glitch from going any further. What if that could be done with threats to a person's health? Investigators from The Cancer Institute of New Jersey and the Environmental & Occupational Health Sciences Institute which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, have discovered that a form of a dietary trace element known as selenium can help reset a cell's "biological clock" when it is disrupted by a chemical cancer-causing agent (carcinogen).

28 Apr 2010